Articles

Artificial intelligence (AI) and machine learning (ML) platforms are becoming essential to the value equation in healthcare and to managing the complexity and range of treatment options within cancer care today. Panelists in this session explored the application of AI and ML technologies and their impact on care, outcomes, cost, providers, pharma, payers, and patients as well as their integrations between electronic medical records and future systems.

A new study has revealed some important information about the behavior of one of the most notorious forms of cancer. Pancreatic cancer, the study found, can readily turn to an alternate source of energy to survive when its primary source, the sugar molecule glucose, is in short supply.

Washington, DC—On September 6, 2023, the Association for Accessible Medicines (AAM), the leading trade association for generic and biosimilar manufacturers, released its 2023 U.S. Generic & Biosimilar Medicines Savings Report highlighting the value of generic and biosimilar medicines.

Crystal S. Denlinger, MD, FACP, has been named the new Chief Executive Officer (CEO) of the National Comprehensive Cancer Network.

Cancer clinical trials offer patients an opportunity to be treated with the most cutting-edge and promising therapies available, but the majority of patients who are offered these trials still are not signing up for them.

To better assist their oncology patients with getting into clinical trials, providers at the University of Florida Health Cancer Center, Gainesville, recently decided that they needed a new kind of navigator: an oncology clinical trial nurse navigator.

On August 14, 2023, the FDA approved melphalan hydrochloride for injection/Hepatic Delivery System (HDS; Hepzato Kit; Delcath Systems) as a liver-directed treatment for use in adults with uveal melanoma and unresectable hepatic metastases affecting <50% of the liver and no extrahepatic disease, or extrahepatic disease that is limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.

On August 14, 2023, the FDA accelerated the approval of elranatamab-bcmm (Elrexfio; Pfizer), a bispecific B-cell maturation antigen–directed CD3 T-cell engager, for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 previous lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody.

On August 9, 2023, the FDA accelerated the approval of talquetamab-tgvs (Talvey; Janssen Biotech), a bispecific GPRC5D-directed CD3 T-cell engager, for the treatment of adults with relapsed or refractory multiple myeloma who have previously received at least 4 lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody.